Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance

By sjmartinez • November 9, 2023

Karpouzas GA, Szekanecz Z, Baecklund E, Mikuls TR, Bhatt DL, Wang C, Sawyerr GA, Chen Y, Menon S, Connell CA, Ytterberg SR, Mortezavi M. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance. Ther Adv Musculoskelet Dis. 2023 Nov 6;15:1759720X231201047. doi: 10.1177/1759720X231201047. PMID: 37942277; PMCID: PMC10629315.

Tags: autoinflammatory conditions, DMARDs, Inflammation, outcome measures, Publications, Rheumatoid arthritis, Rheumatology

The role of declining therapy volumes in skilled nursing facility outcomes: a mediation analysis

Prusynski RA, Humbert A, Amaravadi H, Burke RE, Saliba D, Leland NE, Freburger J, Mroz TM. The role of declining therapy volumes in skilled nursing[...]

Bloodstream Infections Among Veterans With Cardiac Implantable Electronic Devices: Source Identification and Intervention Strategies

Basnet D, Golenbock S, Strymish JM, Mull HJ, Lamkin RP, Shin M, Harvey K, Karchmer AW, Branch-Elliman W. Bloodstream Infections Among Veterans With Cardiac Implantable[...]

FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma

Corren J, Reid F, Moate R, Jimenez E, Sadiq MW, Williams A, Rytelewski M, Cameron-Christie S, Muthas D, Georgi B, Brooks D, Lindqvist E, Kell[...]